While two malaria vaccines are now recommended by the World Health Organization for use in African children, there remains a need for next-generation vaccines that are more efficacious, durable, and cost-effective, and that require fewer doses.

One promising approach is the development of multistage vaccines targeting both the pre-erythrocytic and asexual blood stages of the malaria parasite’s lifecycle. In May 2023, under the Innovations in Malaria Vaccine Development contract, the US Agency for International Development’s Malaria Vaccine Development Program and PATH convened a panel of experts in malaria, vaccine development, regulatory affairs, and the conduct of clinical trials in Africa, Europe, and the United States to consider and inform the development of a comprehensive clinical development plan for a multistage malaria vaccine.

This report summarizes the discussions held during the consultation and outlines the experts' key recommendations to inform a clinical development plan.